Greg Friberg, MD

Vice President and Therapeutic Area Head at Amgen Oncology

Greg received his A.B. degree in biochemistry from Middlebury College and M.D. from New York Medical College. He completed his residency training in Internal Medicine at Dartmouth-Hitchcock Medical Center and his fellowship training in Hematology and Oncology at The University of Chicago Hospitals. As part of his training, he graduated from the University of Chicago Health Sciences Department Clinical Research Training Program specializing in clinical trial design and analysis. He joined the faculty of the University of Chicago thereafter joining the Phase I, Gastrointestinal, and Gynecologic oncology teams where he served as the PI for multiple early phase clinical studies. He published multiple research papers and reviews, and he was an active member of ASCO, the CALGB, and the GOG.

Greg joined Amgen in 2006 as an Associate Medical Director in Oncology Early Development. He served as the team lead for multiple early and mid-stage programs, shepherding molecules though IND filings, into initial human studies, and onto later development. Greg took over as group leader in 2011 and served for 3 years as Therapeutic Area Head, Oncology Early Development and later for 4 months as Early Development Head overseeing (Oncology, Inflammation, Neuroscience, and General Medicine/Bone). Starting in 2014, Greg served as the interim co-TA head for the Hematology / Oncology TA. In 2016 he served as the Global Product General Manager (GPGM) for the early hematology BiTE portfolio.

In 2017 Greg assumed the role of vice president and Therapeutic Area Head, Hematology / Oncology Global Development. In addition, in 2019 Greg assumed the TA Head responsibilities for the Bone franchise.

P.K. Morrow, MD

Vice President of Clinical Development, Amgen Oncology

P.K. earned her Medical Degree at the University of Texas Medical School at Houston, where she was a member of the Alpha Omega Alpha (AOA) Honor Medical Society. Subsequently, she completed her Internal Medicine Residency at Baylor College of Medicine and Hematology/Oncology Fellowship at the University of Texas MD Anderson Cancer Center, where she also served as a Chief Fellow. During her fellowship, she was named Fellow of the Year and earned the ASCO Young Investigator Award for her translational research in angiogenesis.

Prior to joining Amgen, P.K. was an Assistant Professor, Department of Breast Medical Oncology, at the University of Texas MD Anderson Cancer Center. She co-led the development of the first multidisciplinary breast cancer survivorship clinic at MD Anderson and served as the principal investigator of multiple drug studies.

From 2013 through 2015, as the Neupogen® /Neulasta® Global Development Lead and US Medical Lead, P.K. led a cross-functional team in the development and registration of the Neulasta® Onpro™. In addition, she led a pre-clinical and clinical team in the successful submission of the Neupogen® and Neulasta® Acute Radiation Syndrome (ARS) sBLAs, leading to approval of both products for the ARS indication.

From 2014 to 2017, P.K. served as the Therapeutic Area Head for Oncology in the U.S. Medical Organization, where she oversaw U.S. oncology research activities, launch activities for newly approved oncology molecules, medical advocacy efforts, extramural research, and independent medical education grants. During this time, she successfully led the medical launch activities for IMLYGIC®, Kyprolis®, Neulasta Onpro™, and Blincyto®. In addition, P.K. served as the Global Product General Manager for three early-stage oncology molecules focused upon MCL-1 and KRAS G12C. Furthermore, P.K. was appointed by the FDA to be the industry representative to the Oncology Drug Advisory Committee (ODAC) for a four-year term, ending in 2019.

In April 2019, P.K. became Vice President of Global Development and Therapeutic Area Head of Hematology, where she is responsible for guiding and accelerating late development activities addressing both marketed hematology programs (Blincyto and Kyprolis) and guiding the late development of programs that focus upon BCMA, FLT3, CD33, and MCL-1.